NAD+ Without Prescription: 1,000 mg Arrives Undivided

Separating these is most of the work. Once they are apart, almost every confused claim about NAD+ legality sorts itself into one column or another.

The first column is the only one a member of the public transacts directly, and the phrase without prescription describes it accurately for a reason that has nothing to do with a loophole. No prescription is involved because nothing is being dispensed. Research material is sold as a laboratory reagent against an order, on the seller's stated terms that it is not for human or veterinary use.

The middle column is where FDA's compounding rules live, and it is where the interesting NAD+ facts are. The third is where state law lives, and our local NAD+ page deals with it.

Under section 503A of the FD&C Act, a pharmacy may compound from a bulk drug substance that complies with a USP or NF monograph where one exists, or is a component of an FDA-approved drug product where one does not, or appears on FDA's 503A bulks list. That list is still being built, and while it is, FDA operates an interim policy that sorts nominated substances into three categories.

On the category lists updated 14 May 2026, Nicotinamide Adenine Dinucleotide (NAD) appears in category 1, bulk drug substances under evaluation. So does Nicotinamide Adenine Dinucleotide Disodium Reduced (NADH). There is no NAD entry in category 2.

FDA's description of category 1 is worth quoting rather than summarising. These substances "may be eligible for inclusion on the 503A bulks list, were nominated with sufficient supporting information for FDA to evaluate them, and do not appear on any other list", and "FDA does not intend to take action against a compounder for compounding drugs using bulk drug substances listed in category 1, provided that the conditions described in the guidance document are met".

Now the four qualifications that matter, none of which are decoration.

• It is non-enforcement, not approval. The sentence is about what FDA does not intend to do. Nothing in it authorises a product, and no NAD+ drug product is approved.
• It is conditional. The protection applies where the conditions in the guidance are met, and the interim policy is directed at state-licensed pharmacies, federal facilities and licensed physicians. It is a position about compounders, not a permission granted to buyers.
• It is explicitly temporary. FDA states that category 1 substances "may continue to be within the scope of the interim enforcement policy" until the agency decides on inclusion on the 503A bulks list, "or unless the agency removes the substances from category 1 based on, for example, information about safety risks". A list titled under evaluation is not a settled position.
• The list is closing to new entrants. FDA has stated it does not intend to place substances nominated on or after 7 January 2025 into these categories at all.

If you have read that NAD+ is category 2, or banned from compounding, that is wrong on the current documents. It is a common enough error that you should expect to meet it again.

One line on the same document catches people who go looking for the entry themselves, and it is worth knowing before you find it.

Beta-Nicotinamide Adenine Dinucleotide Disodium Salt Trihydrate appears in category 3, bulk drug substances nominated without adequate support. It reads like the same substance under a longer name, and it sits in a materially different position.

FDA describes category 3 substances as ones that "may be eligible for inclusion on the 503A bulks list but were nominated with insufficient supporting information for FDA to evaluate them". Crucially, they "are not eligible for the policy that applies to substances in category 1", and FDA "would consider taking action against a compounder for compounding drug products with this bulk drug substance under its general enforcement policies".

So the difference between the two entries is not academic. One carries an interim non-enforcement position and the other explicitly does not. Category 3 is also not a safety finding, which is the other half of the misreading: it means the nomination lacked the information FDA needed, and the document notes such substances can be re-nominated with sufficient support. Nothing in category 3 says a substance is dangerous. Category 2 is the one that turns on identified safety risks, and no NAD entry appears there.

The accurate answer has three parts, and each of them is narrower than the sentence people usually want.

There is no approved NAD+ drug product. Search the FDA approved drug database and no NAD+ injectable comes back. That is why there is no pharmacy price, no national drug code, no formulary position and no insurance claim to submit for any of the three transactions above.

Research material is sold on labelling terms, not on prescription terms. The listing states laboratory research use only, not for human consumption. That is the basis of the sale, and buying it does not convert it into anything else. Nothing on this site, including our NAD reference page, is written as guidance for use in a person.

Compounded preparations exist, on the interim footing described above. A 503A pharmacy compounding with NAD under the category 1 policy is doing something with a defined regulatory basis, provided it meets the conditions. That path runs through a prescriber, so it is precisely the path that is not without prescription.

One clarification on the precursors, because searches for legality drift into them. NMN and NR are different substances with their own separate regulatory histories, which were not checked for this page and are not asserted here. They are commonly sold as supplements, and a supplement purchase is not the same purchase as a gram of NAD+ from a research supplier. Do not carry a claim about one across to the other.

The absence of a prescription removes a dispensing barrier and a set of checks at the same time, and the second half is the part worth pricing.

• No pharmacist between you and the material. Nobody verifies the container, the concentration, the labelling or the appropriateness of what you bought.
• No recall channel. An approved product has a marketing authorisation holder and a defined route for withdrawing a batch. A research listing has a vendor and an email address.
• No sterility assurance by default. This is the specific failure documented for NAD+. FDA's compounding notice, content current as of 30 October 2024, states that the agency "is aware of compounders using food-grade nicotinamide adenine dinucleotide (NAD+) sold by repackagers to make intravenous products", that food-grade ingredients "are not suitable for compounding sterile drugs without appropriate processing, due to the high risk of contamination with microbes and endotoxins", and that it received adverse event reports after use of NAD+ injectable drugs including "severe chills, shaking, vomiting and fatigue with some requiring medical treatment", consistent with excessive endotoxin levels.

Read alongside the 503A rules, that notice points straight at the document that does the work. FDA's compounding page states that bulk drug substances "must be accompanied by a valid certificate of analysis" and must come from an establishment registered under section 510 of the FD&C Act, and it urges compounders to know their bulks supplier. A buyer without a prescription is the compounder in that sentence, whether or not they think of themselves that way.

So the certificate is the substitute for everything the prescription route would have supplied, and its scope is the whole question. Identity and purity by HPLC and mass spec do not answer an endotoxin question; a bacterial endotoxins result does. Ascension publishes two third-party assays against this listing, Kovera Labs on batch 25-05260628 tested 14 June 2026 and MZ Biolabs on batch 25-01260229 tested 26 January 2026. Match the batch code to the vial, and read what was tested rather than the headline number.

Without a prescription, nobody has decided the concentration, and that is a decision rather than an oversight.

The vial is 1,000 mg of dry coenzyme with no concentration at all until a diluent goes in. Made up to 10 mL it is 100 mg/mL, so one unit on a U-100 barrel is 0.01 mL and holds 1 mg, 10 units draws 10 mg, and a full 100 unit barrel holds 100 mg. Made up to 20 mL it is 50 mg/mL and the same 10 units draws 5 mg. The price does not move: $52.00 with the code, $5.20 per 100 mg, $0.052 for each unit of the 10 mL preparation.

That scale is the thing to keep hold of. On a 10 mg peptide vial the same 10 units draws 500 mcg, so a habit carried across from the rest of this site is wrong by a factor of twenty. Our NAD calculator will run any volume you enter, the reconstitution guide and syringe measurement guide cover the mechanics, and the NAD reference page holds the compound-specific figures. These are laboratory handling numbers for research material and nothing on this page is advice about use in a person.

For the purchase side, the price breakdown covers landed cost and the tiers, and the domestic supply page covers why a US stock position changes the risk profile more than it changes the rate.